Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Endocrine 1Dermatologic 1

Conditions

Melanoma 2Small Cell Lung Carcinoma 1Sarcoma 1Parathyroid Neoplasms 1Neoplasms 1Lung Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Carcinoid Tumor 1Breast Neoplasms 1

Interventions

belinostat 2Trastuzumab 2tipifarnib 1entinostat 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Interleukin-12 Subunit p35 1Interleukin-12 1Indinavir 1Immunotherapy 1Gefitinib 1Fluorouracil 1Drug Therapy 1Denosumab 1Dacarbazine 1Control Groups 1Bortezomib 1Blood Specimen Collection 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parathyroid Neoplasms × Dacarbazine × Thoracic × Clear all
NCT00580320 2016-08-18

Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

Virginia Commonwealth University

Phase 1 Completed
17 enrolled
DermatologicEndocrineHead & NeckSarcomaThoracic

Carcinoid Tumor, Melanoma, Parathyroid Neoplasms, Sarcoma, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡